RxDoctor Payments Data

Laurinda Harjai

Family · Atlanta, GANPI 1134507999

Payments from drug & device makers

$2,768in general payments, 2019–2025

Across 76 payments — averaging $36.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$561
  • Abbott$490
  • Medtronic$418
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$351
  • Novartis$286
  • Alnylam Pharmaceuticals Inc.$151
  • plus $512 from 16 others

What the payments were for

  • Travel & lodging$41815%
  • Food & beverage$2,35085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,768 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$54,990
Medicare patients
323
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$96,648
XareltoRivaroxaban85$84,310
EntrestoSacubitril/Valsartan44$51,788
JardianceEmpagliflozin47$46,419
Metoprolol Succinate177$1,970
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$1,161
ClopidogrelClopidogrel Bisulfate75$726
Atorvastatin Calcium99$648
Amlodipine Besylate154$607
Spironolactone77$501
Torsemide15$416
Ezetimibe17$398
Losartan Potassium54$357
Furosemide94$329
Rosuvastatin Calcium75$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$96,64880 claims
Johnson & JohnsonXarelto$68$84,31085 claims
NovartisEntresto$286$51,78844 claims
Boehringer IngelheimJardiance$42$46,41947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →